Results 21 to 30 of about 53,193 (289)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

JTO Clinical and Research Reports, 2020
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic ...
Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD   +1 more
doaj   +1 more source

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Frontiers in Oncology, 2022
The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs).
Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin   +7 more
doaj   +1 more source

ESMO Updates the Guidelines for the Diagnosis of RET-Altered Cancer to Herald a New Era in Targeted Therapy

healthbook TIMES. Oncology Hematology, 2021
The RET gene encodes a tyrosine kinase receptor that regulates cell survival and proliferation by triggering key downstream pathways.1 RET gene mutations and RET gene fusions are involved in the pathogenesis of lung, thyroid and other cancers.
Alfredo Addeo, Frank Stenner
doaj   +2 more sources

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Frontiers in Oncology, 2021
Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a
Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Gouji Toyokawa, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Kenichi Taguchi, Tatsuro Okamoto, Takashi Seto   +10 more
doaj   +1 more source

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

Frontiers in Oncology, 2023
RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently ...
Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William, William Nassib William   +6 more
doaj   +1 more source

Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2021
Rearranged during transfection (RET) fusions are found in 0.7% to 2% of non-small cell lung cancer (NSCLC). Fusions between RET gene and other domains represent the distinct biological and clinicopathological subtypes of NSCLC.
Qingyun GAO, Junwei SU, Faman XIAO, Xiaocheng LIN, Jinji YANG   +4 more
doaj   +1 more source

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers

European Thyroid Journal, 2023
Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors ...
Markus Eszlinger, Paul Stewardson, John B McIntyre, Adrian Box, Moosa Khalil, Martin Hyrcza, Konstantin Koro, Dean Ruether, Jiahui Wu, Ralf Paschke   +9 more
doaj   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

Characterization and vectorization of siRNA targeting RET/PTC1 in human papillary thyroid carcinoma cells [PDF]

, 2011
RET/PTC1 fusion oncogene is the most common genetic alteration identified to date in thyroid papillary carcinomas (PTC) and represents a good target for small interfering RNA (siRNA).
Massade L.
core   +1 more source

DNA topoisomerases participate in fragility of the oncogene RET [PDF]

, 2013
Fragile site breakage was previously shown to result in rearrangement of the RET oncogene, resembling the rearrangements found in thyroid cancer. Common fragile sites are specific regions of the genome with a high susceptibility to DNA breakage under ...
A Ganguly, A Hellman, A Helmrich, AA Burrow, AJ Swerdlow, AT Jonstrup, AY Chen, BH Long, C Pondarré, CH Cheng, Christine E. Lehman, CM Caudill, D Mishmar, D Vane, DJ Mulvihill, E Grabczyk, E Zlotorynski, F de Vathaire, F Pelliccia, FH Drake, FM Bar, G Abdurashidova, G Capranico, GR Bignell, GR Sutherland, H Zhang, HY Wu, I Bongarzone, J Sambrook, JC Wang, JM Allan, JM Fortune, K Reddy, K Takeuchi, KR Hande, KW Gow, L Enewold, L Postow, Laura W. Dillon, LB Travis, Le Beau, Levi C. T. Pierce, LF Liu, LW Dillon, LW Dillon, M Drolet, M Gandhi, M Zuker, MB Smith, MD Been, MD Been, MF Arlt, MN Nikiforova, MS Kim, NR Lemoine, O Handt, P Boffetta, PA Smanik, R Garcia-Carbonero, R Venkitaraman, RT Hay, S Anderson, S Corbin, S Klugbauer, S McAvoy, S Tuduri, S Wada, SG Durkin, SG Durkin, SJ Froelich-Ammon, SM Jhiang, SM Vos, SN Shah, T Kohno, T Kondo, T Syrovets, TW Glover, TW Glover, Valentin V Rybenkov, X Li, Y Lin, Y Lin, YE Nikiforov, YE Nikiforov, YE Nikiforov, Yuh-Hwa Wang, Yuri E. Nikiforov   +86 more
core   +6 more sources